On Mar. 10, 2021, CEPI, the Coalition for Epidemic Preparedness Innovations, and VBI Vaccines announced a partnership to develop VBIﾒs enveloped virus like particle (eVLP) vaccine candidates against SARS-CoV-2 variants, including the B.1.351 variant, also known as 501Y.V2, first identified in South Africa.